Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NYSE MKT LLC
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Medical Equipment

ISR:US

1.8400 USD 0.1800 8.91%

As of 20:04:05 ET on 05/22/2015.

Snapshot for IsoRay Inc (ISR)

Open: 1.8100 Day's Range: 1.7500 - 2.1500 Volume: 13,462,188
Previous Close: 2.0200 52wk Range: 1.2200 - 3.7900 1-Yr Rtn: -18.58%

Stock Chart for ISR

No chart data available.
  • ISR:US 1.8400
  • 1D
  • 1M
  • 1Y
2.0200
Interactive ISR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ISR

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.0700
Est. EPS (USD) (06/2015) -0.0600
Est. PEG Ratio -
Market Cap (M USD) 101.03
Shares Outstanding (M) 54.91
30 Day Average Volume 4,764,225
Price/Book (mrq) 4.4827
Price/Sale (ttm) 23.8531
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ISR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ISR

IsoRay, Inc., through its subsidiary, produces a brachytherapy seed, used to treat prostate and other cancers. The Company's seed delivers more than 90 percent to its total radiation dose in less the 33 days, reducing the incidence of common brachytherapy side effects.

Dwight BabcockChairman/CEOBrien L RagleChief Financial Officer
Lane A BrayChief ChemistFredric Swindler "Fred"Vice President
More Company Profile & Key Executives for ISR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil